Date | Price Target | Rating | Analyst |
---|---|---|---|
5/30/2024 | $372.00 | Neutral | Goldman |
5/22/2024 | $392.00 | Hold → Buy | Needham |
1/31/2024 | $315.00 → $360.00 | Hold → Buy | Canaccord Genuity |
10/20/2023 | $345.00 | Buy | ROTH MKM |
9/5/2023 | $310.00 → $315.00 | Neutral → Buy | BofA Securities |
3/29/2023 | $287.00 | Neutral | UBS |
1/25/2023 | Sector Weight | KeyBanc Capital Markets | |
1/9/2023 | $240.00 → $284.00 | Sector Perform → Outperform | RBC Capital Mkts |
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
SC 13G/A - STRYKER CORP (0000310764) (Subject)
Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stry
SAN JOSE, California, USA, July 31, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's commitment to advancing surgical solutions in breast cancer care. The MOLLI 2 localization system is designed for ease of use and reliability to support a more efficient surgical workflow. The MOLLI Mar
Portage, Michigan, July 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the second quarter of 2024: Second Quarter Results Reported net sales increased 8.5% to $5.4 billionOrganic net sales increased 9.0%Reported operating income margin of 19.4%Adjusted operating income margin(1) increased 30 bps to 24.6%Reported EPS increased 10.9% to $2.14Adjusted EPS(1) increased 10.6% to $2.81 Second Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 9.0 % (0.8) % 9.8 % 0.1 % 9.7
Goldman initiated coverage of Stryker with a rating of Neutral and set a new price target of $372.00
Needham upgraded Stryker from Hold to Buy and set a new price target of $392.00
Canaccord Genuity upgraded Stryker from Hold to Buy and set a new price target of $360.00 from $315.00 previously
10-Q - STRYKER CORP (0000310764) (Filer)
8-K - STRYKER CORP (0000310764) (Filer)
SD - STRYKER CORP (0000310764) (Filer)
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today the addition of Emory Rooney as Executive Vice President, Sales. In this role, Rooney will lead U.S. market growth and sales efforts. Rooney comes to Spineology with extensive spine sales experience, having served in Medical Device fields related to spinal implants and navigation for nearly 20 years. "The addition of Emory adds even further conviction about our clear opportunity for growth at Spineology," said Brian Snider, Chief Executive Officer at Spineology. "I have had the opportunity to work with Emory and have seen his impact leading sales teams, building new terri
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
Portage, Michigan, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, at the Encore Boston Harbor. Spencer Stiles, Group President, Orthopaedics and Spine, and Jason Beach, Vice President, Finance and Investor Relations will represent the Company in a session scheduled for 3:00 pm Eastern Time. A simultaneous webcast and replay of the Company's presentation will be available on Stryker's website at www.stryker.com. The webcast will be archived on the Investor Relations page of this site. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is d
Portage, Michigan, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to acquire care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. The acquisition will strengthen Stryker's growing healthcare IT offering and wirelessly connected medical device portfolio. This growing segment is of increasing importance as Stryker's customers continue to face nursing shortages, employee retention challenges, overworked and cognitively burdened staff, and a rise in workplace safety concerns. care.ai adds complementary tech
Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stry
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
4 - STRYKER CORP (0000310764) (Issuer)
Stryker's (NYSE:SYK) short percent of float has risen 7.55% since its last report. The company recently reported that it has 4.11 million shares sold short, which is 1.14% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.41 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
Stryker (NYSE:SYK) has outperformed the market over the past 10 years by 4.7% on an annualized basis producing an average annual return of 15.6%. Currently, Stryker has a market capitalization of $130.48 billion. Buying $1000 In SYK: If an investor had bought $1000 of SYK stock 10 years ago, it would be worth $4,267.32 today based on a price of $342.50 for SYK at the time of writing. Stryker's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed
Morgan Stanley analyst Drew Ranieri maintains Stryker (NYSE:SYK) with a Equal-Weight and raises the price target from $345 to $350.